Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of HTL0009936 MR Formulations in Healthy Subjects
NCT02710188Phase 1Completed
- Sponsor
- Nxera Pharma
- Start
- Feb 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HTL0009936 in Alzheimer's disease (AD) (2 arms), sponsored by Nxera Pharma. Primary endpoints: Lag time at 14 weeks, Relative Bioavailability at 14 weeks and 12 more. Started Feb 2016; status: completed.
02
Drugs
HTL0009936
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02710188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02710188.